NKGen Biotech's CEO will present Phase 1 clinical trial results for NK cell therapy in Alzheimer's at AD/PD™ 2025. NKGen Biotech, Inc. announced that its CEO, Dr. Paul Y. Song, will present at the ...
Some results have been hidden because they may be inaccessible to you
Show inaccessible results